English: Combination of two brain diagrams in one for comparison. In the left normal brain, in the right brain of a person with Alzheimer’s disease. Diagram of the brain of a person with Alzheimer’s Disease. Diagram of a normal brain. (Photo credit: Wikipedia)
Researchers at Yale School of Medicine have discovered a new drug compound that reverses the brain deficits of Alzheimer’s disease in an animal model.
Their findings are published in the Aug. 5 issue of the journal PLoS Biology.
The compound, TC-2153, inhibits the negative effects of a protein called STtriatal-Enriched tyrosine Phosphatase (STEP), which is key to regulating learning and memory. These cognitive functions are impaired in Alzheimer’s.
“Decreasing STEP levels reversed the effects of Alzheimer’s disease in mice,” said lead author Paul Lombroso, M.D., professor in the Yale Child Study Center and in the Departments of Neurobiology and Psychiatry at Yale School of Medicine.
Lombroso and co-authors studied thousands of small molecules, searching for those that would inhibit STEP activity. Once identified, those STEP-inhibiting compounds were tested in brain cells to examine how effectively they could halt the effects of STEP. They examined the most promising compound in a mouse model of Alzheimer’s disease, and found a reversal of deficits in several cognitive exercises that gauged the animals’ ability to remember previously seen objects.
Read more . . .
The Latest on: Alzheimer’s drug
via Google News
The Latest on: Alzheimer’s drug
- History of depression, anxiety linked to earlier Alzheimer's onseton February 26, 2021 at 12:05 am
People with Alzheimer's disease often have a history of depression or anxiety, which might mean an earlier emergence of memory and thinking problems, a preliminary study suggests.
- Strategic hires strengthen leadership team and position ADDF to expand its notable role in Alzheimer's drug developmenton February 24, 2021 at 6:30 pm
The Alzheimer's Drug Discovery Foundation (ADDF), a leading nonprofit solely focused on accelerating the development of drugs for Alzheimer's disease and related dementias, announced today a ...
- The Alzheimer's Drug Discovery Foundation Appoints Karen Harris, Chief Financial Officer, and Dr. Mark Forman, Senior Director of Drug Developmenton February 24, 2021 at 4:30 pm
The Alzheimer's Drug Discovery Foundation (ADDF), a leading nonprofit solely focused on accelerating the development of drugs for Alzheimer's disease and related dementias, announced today a ...
- Cytox Launches genoSCORETM-LAB Test to Predict the Risk of Developing Alzheimer’s Diseaseon February 23, 2021 at 11:07 pm
Cytox Ltd, which provides non-invasive, risk assessment and patient stratification tools for Alzheimer's disease (AD) and dementia, announces the launch of its new genetic test, genoSCORETM-LAB, that ...
- Eli Lilly CEO: We see a path to have an Alzheimer's disease-modifying drugon February 22, 2021 at 8:51 pm
Eli Lilly CEO Dave Ricks how the drugmaker has worked for decades to find a way to treat Alzheimer's disease. The company says a Phase 2 trial of donanemab reveals that the drug can slow progression ...
- Eli Lilly CEO on Alzheimer's drug candidate update, Covid antibody treatmenton February 22, 2021 at 3:15 pm
Eli Lilly CEO Dave Ricks joined Jim Cramer on "Mad Money" to discuss promising results from an Alzheimer's drug study, the company's Covid-19 antibody treatment program and migraine product.
- United States Alzheimer's Disease Drug Market 2021-2026: Marketed Branded/Generis/ Drugs Dosage, Patent and Price Insighton February 19, 2021 at 6:00 am
The "US Alzheimer's Disease Drug Market, Dosage, Price & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering. We sift through this volatile market for consistent ...
- A safer Alzheimer's drug than Biogen's aducanumab? Denali-WashU drug shows better profile in miceon February 18, 2021 at 5:25 am
In 2018, a collaboration between Washington University and Denali Therapeutics resulted in an antibody drug that showed promise as a potential Alzheimer’s therapy. Now, the team has returned with ...
- United States Alzheimer's Disease Drug Market, Dosage, Price & Clinical Trials Analysis 2021-2026 - ResearchAndMarkets.comon February 17, 2021 at 6:45 am
The "US Alzheimer's Disease Drug Market, Dosage, Price & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.
- Machine learning identifies candidates for drug repurposing in Alzheimer’s diseaseon February 15, 2021 at 2:33 am
Clinical trials of novel therapeutics for Alzheimer’s Disease (AD) have provided largely negative results, so far. Here, the authors present a machine learning framework that quantifies potential ...
via Bing News
2 Comments
kennard peterson
do they sell tcp2153 and cost thank you
innovation
Please contact the original author for further information.